Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Assets Average: 2009-2025

Historic Assets Average for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $30.1 million.

  • Northwest Biotherapeutics' Assets Average rose 4.54% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 4.54%. This contributed to the annual value of $27.3 million for FY2024, which is 7.76% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Assets Average stood at $30.1 million, which was up 5.44% from $28.5 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Assets Average ranged from a high of $35.4 million in Q1 2022 and a low of $27.1 million during Q1 2025.
  • Its 3-year average for Assets Average is $29.2 million, with a median of $28.8 million in 2024.
  • In the last 5 years, Northwest Biotherapeutics' Assets Average surged by 229.66% in 2021 and then declined by 12.09% in 2024.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Assets Average stood at $34.2 million in 2021, then fell by 8.72% to $31.2 million in 2022, then declined by 4.91% to $29.7 million in 2023, then dropped by 5.57% to $28.0 million in 2024, then increased by 4.54% to $30.1 million in 2025.
  • Its Assets Average was $30.1 million in Q3 2025, compared to $28.5 million in Q2 2025 and $27.1 million in Q1 2025.